Astellas Pharma (ALPMY) Earnings Date, Estimates & Call Transcripts $14.21 -0.22 (-1.52%) As of 05/22/2026 03:58 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock Astellas Pharma Earnings Summary Astellas Pharma released Q4 2026 earnings on April 27, 2026, reporting an EPS of $0.33, which beat analysts' consensus estimates of $0.19 by $0.14. Quarterly revenue was reported to be $3.38 billion, above analyst estimates of $3.28 billion. With a trailing EPS of $1.07 and a P/E Ratio of 13.23, Astellas Pharma's earnings are expected to grow 3.10% next year, from $1.29 to $1.33 per share. Q4 2026 Earnings ResourcesQ4 2026 Earnings ReportALPMY Upcoming EarningsAstellas Pharma's next earnings date is estimated for Wednesday, July 29, 2026, based on past reporting schedules. Upcoming Q1 Earnings DateJul. 29Before Market OpensEstimatedConsensus EPS (Apr. 27) $0.19 Actual EPS (Apr. 27) $0.33 Beat By $0.14 Actual Revenue (Apr. 27) $3.38B Get Astellas Pharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your inbox. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataALPMY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALPMY Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Astellas Pharma Analyst EPS EstimatesCurrent Year EPS Consensus Estimate $1.29 EPSNext Year EPS Consensus Estimate $1.33 EPS Astellas Pharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 7/29/2026(Estimated)--------4/27/2026Q4 2026$0.1941$0.33+$0.1359$0.15$3.28B$3.38B2/4/2026Q3 2026$0.2916$0.44+$0.1484$0.36$3.21B$3.67B10/30/2025Q2 2026$0.1993$0.30+$0.1007$0.30$3.14B$3.45B7/30/2025Q1 2026$0.1356$0.40+$0.2644$0.26$3.20B$3.41B4/25/2025Q4 2025$0.1474$0.27+$0.1226$0.27$3.02B$3.22B2/4/2025Q3 2025-$0.30--$0.36--10/30/2024Q2 2025-$0.13-$0.13-$3.11B8/1/2024Q1 2025-$0.24-$0.35-$3.03B Data powered by Fiscal.ai. Astellas Pharma Earnings - Frequently Asked Questions When is Astellas Pharma's earnings date? Astellas Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 29th, 2026 based off last year's report dates. Learn more on ALPMY's earnings history. Did Astellas Pharma beat their earnings estimates last quarter? In the previous quarter, Astellas Pharma (OTCMKTS:ALPMY) reported $0.33 earnings per share (EPS) to beat the analysts' consensus estimate of $0.19 by $0.14. Learn more on analysts' earnings estimate vs. ALPMY's actual earnings. How much revenue does Astellas Pharma generate each year? Astellas Pharma (OTCMKTS:ALPMY) has a recorded annual revenue of $14.21 billion. How much profit does Astellas Pharma generate each year? Astellas Pharma (OTCMKTS:ALPMY) has a recorded net income of $1.94 billion. ALPMY has generated $1.07 earnings per share over the last four quarters. What is Astellas Pharma's price-to-earnings ratio? Astellas Pharma (OTCMKTS:ALPMY) has a trailing price-to-earnings ratio of 13.23 and a forward price-to-earnings ratio of 11.02. What is Astellas Pharma's EPS forecast for next year? Astellas Pharma's earnings are expected to grow from $1.29 per share to $1.33 per share in the next year, which is a 3.10% increase. More Earnings Resources from MarketBeat Related Companies CHGCY Earnings Date TAK Earnings Date ONC Earnings Date DSNKY Earnings Date ZTS Earnings Date UTHR Earnings Date MKKGY Earnings Date NBIX Earnings Date SGIOY Earnings Date SMMT Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay BullishTarget Shows Strengths, But Analysts Want to See MoreLowe's Finds Support at $215 After Q1 Earnings Sell-Off This page (OTCMKTS:ALPMY) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
